Onkologie. 2018:12(3):139-143 | DOI: 10.36290/xon.2018.026

Treatment of repeatedly relapsing chronic lymphocytic leukemia

Pavel Vodárek, Martin Šimkovič
IV. interní hematologická klinika LF UK a FN Hradec Králové

Chronic lymphocytic leukemia is one of the most common lymphoproliferative disorders in western population. Course andprognosis of the disease are very variable and they are influenced, among other factors, by typical cytogenetic changes and geneticmutations. Many patients never require treatment, whereas others die in spite of the treatment in short time from diagnosis.The treatment is based on classical chemotherapy, monoclonal antibodies and also targeted therapy, or possibly combinationof these. Described case shows a significant part of current treatment approaches – chemoimmunotherapy with fludarabine,cyclophosphamide and rituximab in the 1. line of treatment, retreatment with the same combination in the situation of laterelapse, treatment with idelalisib, high-dose corticosteroids and finally with venetoclax. We discuss different options, especiallyregarding modern targeted therapy, with emphasis on practical aspects as well as optimal sequencing of these options, includingallogeneic hematopoietic stem cell transplantation.

Keywords: chronic lymphocytic leukemia, relapsed, refractory, ibrutinib, idelalisib, venetoclax

Published: June 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vodárek P, Šimkovič M. Treatment of repeatedly relapsing chronic lymphocytic leukemia. Onkologie. 2018;12(3):139-143. doi: 10.36290/xon.2018.026.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Doubek M, Panovská A, Janča J, et al. Co víme o incidenci chronické lymfocytární leukemie (CLL), a kde a jak jsou nemocní s CLL léčeni? Trans Hemat Dnes 2010; suppl 1: 11-15.
    2. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8(10): 1640-1645.
    3. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94(6): 1848-1854. Go to original source...
    4. Smolej L, Špaček M, Obrtlíková P, et al. Doporučení pro diagnostiku a léčbu chronické lymfocytární leukémie (CLL) [online]. Praha: Česká skupina pro chronickou lymfocytární leukémii, sekce České hematologické společnosti České lékařské společnosti Jana Evangelisty Purkyně (ČHS ČLS JEP) 2016 [cit. 10-04-2018]. Dostupné z: http://www.cll.cz/novinky/
    5. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 2016; 127(2): 208-215. Go to original source...
    6. Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 17(7): 928-942. Go to original source... Go to PubMed...
    7. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370(12): 1101-1110. Go to original source... Go to PubMed...
    8. O'Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 2016; 17(10): 1409-1418. Go to original source... Go to PubMed...
    9. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373(25): 2425-2437. Go to original source...
    10. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370(11): 997-1007. Go to original source...
    11. Lampson BL, Kasar SN, Matos TR, Morgan EA. Idelalisib given frontline for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 2016; 128(2): 195-203. Go to original source... Go to PubMed...
    12. O'Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-na?ve older patients with chronic lymphocytic leukemia. Blood 2015; 126(25): 2686-2694. Go to original source...
    13. Kreuzer KA, Furman RR, Stilgenbauer S, et al. Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia. Blood 2016; 128(22): 192. Go to original source...
    14. Thompson PA, O'Brien SM, Wierda WG, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 2015; 121(20): 3612-3621. Go to original source...
    15. Seymour JF, Kipps TJ, Eichhorst BF, et al. Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. 2017 ASH annual meeting, 2017. Abstract LBA-2. Go to original source...
    16. Jones JCMY, Mato AR, Furman RR, et al. Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib. 2016 ASH annual meeting, 2016. Abstract 637. Go to original source...
    17. Souhrn údajů o přípravku Venclyxto (online). Praha: Státní ústav pro kontrolu léčiv 2018 (cit. 21-04-2018). Dostupné z: http://www.sukl.cz/modules/medication/search.php?data%5Bsearch_for%5D=venclyxto&data%5Bcode%5D=&data%5Batc_group%5D=&data%5Bmaterial%5D=&data%5Bpath%5D=&data%5Breg%5D=&data%5Bradio%5D=none&data%5Brc%5D=&data%5Bchbox%5D%5B%5D=braill-yes&data%5Bchbox%5D%5B%5D=braill-no&data%5Bchbox%5D%5B%5D=braill-def&data%5Bwith_adv%5D=0&search=Vyhledat&data%5Blisting%5D=20
    18. Mato AR, Tam CS, Alan JN, et al. Disease and Patient Characteristics, Patterns of Care, Toxicities, and Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax: A Multicenter Study of 204 Patients. 2017 ASH annual meeting, 2017. Abstract 4315.
    19. Kharfan-Dabaja MA, Kumar A, Mehdi Hamadani M, et al. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2016; 22(12): 2117-2125. Go to original source... Go to PubMed...
    20. Smolej L, Doubek M, Panovská A, et al. Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. Leuk. Res 2012; 36: 1278-1282. Go to original source... Go to PubMed...
    21. Fiegl M, Stauder R, Steurer MA, et al. Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Ann Hematol 2014; 93(2): 267-277. Go to original source... Go to PubMed...
    22. Smolej L, Procházka V, Špaček M, et al. Doporučení pro léčbu alemtuzumabem u chronické lymfocytární leukémie (CLL). Vnitř Lék 2012; 58(3): 232-236. Go to PubMed...
    23. Fischer K, Hallek M. Optimizing frontline therapy of CLL based on clinical and biological factors. Hematology Am Soc Hematol Educ Program 2017: 338-345. Go to original source... Go to PubMed...
    24. Davids MS. How should we sequence and combine novel therapies in CLL. Hematology Am Soc Hematol Educ Program 2017: 346-353. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.